Appeal No. 2002-0522 Page 2
Application No. 09/552,543
potassium channel activators, beta-adrenergic agents, antiarrhythmic agents,
diuretics, and thrombolytic agents.
The examiner does not rely on any references.
Claims 23, 24, 26, and 27 stand rejected under 35 U.S.C. § 112, first
paragraph, as lacking an adequate written description in the specification.
We affirm.
Background
The specification discloses that “[c]ompounds of the formula I [chemical
formula omitted] and pharmaceutically acceptable salts thereof are endothelin
receptor antagonists useful, inter alia, as antihypertensive agents.” Page 1.
More specifically, “[t]he compounds of formula I are antagonists of ET-1, ET-2
and/or ET-3 and are useful in treatment of all endothelin-dependent disorders.
They are thus useful as antihypertensive agents. By the administration of a
composition having one (or a combination) of the compounds of this invention,
the blood pressure of a hypertensive mammalian (e.g. human) host is reduced.”
Pages 8-9.
The specification also discloses that “[t]he compounds of the present
invention are also useful in the treatment of” a variety of other disorders. See
pages 9-10. “The compounds of this invention can also be formulated in
combination with endothelin converting enzyme (ECE) inhibitors . . .; platelet
activating factor (PAF) antagonists; angiotensin II (AII) receptor antagonists;
renin inhibitors; angiotensin converting enzyme (ACE) inhibitors . . .; neutral
endopeptidase (NEP) inhibitors; HMG CoA reductase inhibitors . . .; squalene
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007